0 334

Cited 17 times in

Long-term cardiovascular outcomes differ across metabolic dysfunction-associated fatty liver disease subtypes among middle-aged population

DC Field Value Language
dc.contributor.author김승업-
dc.contributor.author김현창-
dc.contributor.author이호규-
dc.contributor.author임태섭-
dc.date.accessioned2023-03-03T02:48:41Z-
dc.date.available2023-03-03T02:48:41Z-
dc.date.issued2022-12-
dc.identifier.issn1936-0533-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/192903-
dc.description.abstractBackground and aims: The new metabolic dysfunction-associated fatty liver disease (MAFLD) criteria include the following three distinct subtypes: MAFLD with diabetes mellitus (DM), overweight/obese (OW), or lean/normal weight with metabolic dysfunction. We investigated whether long-term cardiovascular disease outcomes differ across the MAFLD subtypes. Methods: From a nationwide health screening database, we included 8,412,730 participants (48.6% males) aged 40-64 years, free of cardiovascular disease history, between 2009 and 2010. Participants were categorized into non-MAFLD, OW-MAFLD, lean-MAFLD, and DM-MAFLD. The primary outcome was a composite cardiovascular disease event, including myocardial infarction, ischemic stroke, heart failure, or cardiovascular disease-related death. The presence of advanced liver fibrosis was estimated using a BARD score ≥ 2. Results: Among the study participants, 3,087,640 (36.7%) had MAFLD, among which 2,424,086 (78.5%), 170,761 (5.5%), and 492,793 (16.0%) had OW-MAFLD, lean-MAFLD, and DM-MAFLD, respectively. Over a median follow-up period of 10.0 years, 169,433 new cardiovascular disease events occurred. With the non-MAFLD group as reference, multivariable-adjusted hazard ratios (95% confidence intervals) for cardiovascular disease events were 1.16 (1.15-1.18), 1.23 (1.20-1.27), and 1.82 (1.80-1.85) in the OW-MAFLD, lean-MAFLD, and DM-MAFLD groups, respectively. Participants with lean-MAFLD or DM-MAFLD had a higher cardiovascular disease risk than those with OW-MAFLD, irrespective of metabolic abnormalities or comorbidities. The presence of advanced liver fibrosis was significantly associated with a higher cardiovascular disease risk in each MAFLD subtype. Conclusion: Long-term cardiovascular disease outcomes differed across the MAFLD subtypes. Further studies are required to investigate whether preventive or therapeutic interventions should be optimized according to the MAFLD subtypes.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherSpringer-
dc.relation.isPartOfHEPATOLOGY INTERNATIONAL-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHLiver Cirrhosis / epidemiology-
dc.subject.MESHLiver Diseases*-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHMyocardial Infarction* / epidemiology-
dc.subject.MESHNon-alcoholic Fatty Liver Disease* / epidemiology-
dc.subject.MESHObesity / complications-
dc.subject.MESHObesity / epidemiology-
dc.subject.MESHRisk Factors-
dc.titleLong-term cardiovascular outcomes differ across metabolic dysfunction-associated fatty liver disease subtypes among middle-aged population-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorHokyou Lee-
dc.contributor.googleauthorTae Seop Lim-
dc.contributor.googleauthorSeung Up Kim-
dc.contributor.googleauthorHyeon Chang Kim-
dc.identifier.doi10.1007/s12072-022-10407-7-
dc.contributor.localIdA00654-
dc.contributor.localIdA01142-
dc.contributor.localIdA05838-
dc.contributor.localIdA03414-
dc.relation.journalcodeJ00986-
dc.identifier.eissn1936-0541-
dc.identifier.pmid36070124-
dc.identifier.urlhttps://link.springer.com/article/10.1007/s12072-022-10407-7-
dc.subject.keywordCardiovascular disease-
dc.subject.keywordFatty liver-
dc.subject.keywordMetabolic dysfunction-associated fatty liver disease-
dc.subject.keywordNon-alcoholic fatty liver disease-
dc.subject.keywordSubtype-
dc.contributor.alternativeNameKim, Seung Up-
dc.contributor.affiliatedAuthor김승업-
dc.contributor.affiliatedAuthor김현창-
dc.contributor.affiliatedAuthor이호규-
dc.contributor.affiliatedAuthor임태섭-
dc.citation.volume16-
dc.citation.number6-
dc.citation.startPage1308-
dc.citation.endPage1317-
dc.identifier.bibliographicCitationHEPATOLOGY INTERNATIONAL, Vol.16(6) : 1308-1317, 2022-12-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Preventive Medicine (예방의학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.